Rovi, ES0157261019

Rovi stock sits 33.10 percent below its 52-week high

Published on 10/19/2026 at 09:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Rovi stock costs EUR 58.00 on October 19, 2026, below its EUR 86.70 high. Nine-month results are due November 5, 2026.

Reporting date and operating scale

  • Rovi's next nine-month results are scheduled for November 5, 2026.
  • First-half revenue reached EUR 357 million in 2026, up 13 percent year over year.
  • Rovi stock was trading at EUR 58.00 at 9:22 a.m. CEST at Lang & Schwarz on October 19, 2026.
Rovi, ES0157261019, Illustration mit AI erstellt.

Rovi (ISIN ES0157261019) was trading at EUR 58.00 at Lang & Schwarz on October 19, 2026, at 9:22 a.m. CEST, while its 52-week high stood at EUR 86.70. The next company milestone is the nine-month 2026 report scheduled for November 5, 2026, according to Rovi.

Operating scale sets the baseline

Rovi's first-half figures provide the clearest operating reference ahead of that report. Revenue increased 13 percent year over year to EUR 357 million in the first half of 2026, while gross profit rose 21 percent to EUR 237.1 million. Gross margin improved by 6.5 percentage points to 68.9 percent, according to Yahoo Finance.

The profit comparison was even sharper. Net income reached EUR 84.4 million in the first half of 2026, up 113 percent from the first half of 2025, while the CDMO business grew 38 percent during the period. The figures make contract manufacturing and margin delivery central measures for the November update.

What does November 5 mean?

The scheduled report follows three dated milestones. On May 6, 2026, Rovi reported first-quarter revenue of EUR 154.7 million and a gross-margin expansion of 3.8 percentage points. On July 23, 2026, the company reported first-half total revenue growth of 13.2 percent and gross-margin expansion of 6.5 percentage points. On November 5, 2026, Rovi is scheduled to publish nine-month financial results, according to Rovi.

Analyst target stays above the quote

Jefferies retained a hold recommendation while cutting its price target from EUR 83.50 to EUR 64.20 on May 13, 2026, citing uncertainty after disappointing divisional results, as reported by Bolsamania. The target remains above the current euro quote, but the November figures will test whether CDMO growth can offset pressure in other businesses.

Stock remains below its yearly high

Rovi's EUR 58.00 quote sits within a 52-week range of EUR 53.10 to EUR 86.70, based on the October 16, 2026 market reference. The gap to the high keeps the upcoming report focused on execution rather than a fresh price record.

Rovi was trading at EUR 58.00 at Lang & Schwarz on October 19, 2026, at 9:22 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Rovi stock.

Rovi stock facts

  • Company: Laboratorios Farmacéuticos ROVI, S.A.
  • ISIN: ES0157261019
  • Ticker: ROVI
  • Primary exchange: BME
  • Price Lang & Schwarz (as of October 19, 2026, 9:22 a.m. CEST): EUR 58.00
  • Market capitalization: EUR 3.0 billion (as of October 16, 2026)
  • 52-week range: EUR 53.10-EUR 86.70 (as of October 16, 2026)
  • Sector / Industry: Health care / Pharmaceuticals

Market context: Market report IBEX 35.

More news and analyses on Rovi stock

Disclaimer...
en | ES0157261019 | ROVI | boerse | 70359428 | bgmi